Proteomic profiling reveals treatment-dependent inflammatory signatures and identifies biomarkers of refractory age-related macular degeneration.

Front Pharmacol · 2026 · PMC13315084 · PMID 42382171

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In contrast, brolucizumab-treated patients showed a trend in the increase in the expression of numerous inflammatory molecules following two injections.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.